7:11AM Alkermes beats by $0.07, beats on revs; raises FY13 EPS, rev guidance above consensus (ALKS) 18.52 : Reports Q2 (Sep) earnings of $0.17 per share, $0.07 better than the Capital IQ Consensus Estimate of $0.10; revenues rose 72.2% year/year to $124 mln vs the $122.49 mln consensus.
Co raises guidance for FY13, sees EPS of $0.88-1.02 vs. $0.77 Capital IQ Consensus Estimate; sees FY13 revs of $510-540 mln vs. $519.09 mln Capital IQ Consensus Estimate.
"In September, we updated our expectations for improved non-GAAP net income and free cash flow for fiscal 2013, reflecting the impact of the successful refinancing of the term loans used to fund the merger. Today, we are further improving our financial expectations for fiscal 2013 based on strong operational performance in the first six months, and we now expect Alkermes to generate between $120 million and $140 million in non-GAAP net income this fiscal year."
Co raises guidance for FY13, sees EPS of $0.88-1.02 vs. $0.77 Capital IQ Consensus Estimate; sees FY13 revs of $510-540 mln vs. $519.09 mln Capital IQ Consensus Estimate.
"In September, we updated our expectations for improved non-GAAP net income and free cash flow for fiscal 2013, reflecting the impact of the successful refinancing of the term loans used to fund the merger. Today, we are further improving our financial expectations for fiscal 2013 based on strong operational performance in the first six months, and we now expect Alkermes to generate between $120 million and $140 million in non-GAAP net income this fiscal year."
Recent ALKS News
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting • Business Wire • 04/16/2026 11:00:00 AM
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry • Business Wire • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:56:39 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 09:16:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 09:11:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 09:04:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:16:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 10:58:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:13:44 PM
- Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 • Business Wire • 04/01/2026 11:00:00 AM
- Alkermes shares jump 13% after Lilly announces sleep-disorder acquisition • IH Market News • 03/31/2026 02:55:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/27/2026 09:21:57 PM
- Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program • Business Wire • 03/12/2026 11:00:00 AM
- Alkermes to Present at the Stifel 2026 Virtual CNS Forum • Business Wire • 03/10/2026 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:21:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:19:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:17:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:12:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:15:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:07:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 09:36:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:40:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:40:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:39:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:37:24 PM

